As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
On Wednesday evening at PlayGround Global in Palo Alto, some very smart people who are building things you don’t understand yet will explain what’s coming. This is the final StrictlyVC event of 2025, and truly, the lineup is ridiculous.